1-(4-Methylcarbamoylaminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine | 143692-25-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 1-(4-Methylcarbamoylaminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine
• 英文别名: 1-methyl-3-[4-(8-methyl-9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)phenyl]urea
• CAS: 143692-25-5
• 化学式: C₁₉H₁₈N₄O₃
• 分子量: 350.377
• InChiKey: RERLZRQSLYQZBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  84.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  异氰酸甲酯 、 1-(4-氨基苯基)-4-甲基-7,8亚甲基二氧-5H-2,3-苯并二氮杂卓盐酸盐 在 raw product 、 乙醇 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 24.0h， 以gave 0.85 g (71.4%) of the aimed product, m.p.: 223°-224° C. (decomp.)的产率得到1-(4-Methylcarbamoylaminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine
  参考文献：
  名称：

  N-acyl-2,3-benzodiazepine derivatives, pharmaceutical compositions

  摘要：

  本发明涉及一种新的N-酰基-2,3-苯并二氮平衍生物，其一般式为(I)，其立体异构体和酸加成盐，含有它们的制药组合物以及其制备方法。在一般式(I)中，可以在说明书中找到化合物的更完整描述。一般式(I)的化合物具有有价值的中枢神经系统效应，特别是肌肉松弛、抗惊厥和神经保护作用。因此，它们可能对治疗各种中枢神经系统起源的疾病有用。

  公开号：

  US05459137A1

文献信息

• N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of
  申请人：Gyogyszerkutato Intezet Kv.

  公开号：US05521174A1

  公开（公告）日：1996-05-28

  The invention relates to novel N-acyl-2,3-benzodiezapine derivatives and a method of treating spasms of the skeletal musculature therewith.

  这项发明涉及新颖的N-酰基-2,3-苯并二氮杂平衍生物及其治疗骨骼肌肉痉挛的方法。
• N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions
  申请人：Gyogyszerkutato Intezet

  公开号：US05519019A1

  公开（公告）日：1996-05-21

  The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) R stands for a C.sub.1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C.sub.1-4 alkylamino, di(C.sub.1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C.sub.1-5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R.sup.1 means hydrogen; or R.sup.1 is absent when a double bond exists between the N(3) and C(4) atoms; R.sup.2 means a C.sub.1-3 alkyl group; or R.sup.1 and R.sup.2 together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R.sup.3 means hydrogen or a C.sub.1-4 alkanoyl group; R.sup.4 represents hydrogen; a C.sub.1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C.sub.1-4 alkylamino, di(C.sub.1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropane-carbonyl, C.sub.1-5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R.sup.3 and R.sup.4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

  该发明涉及一种新颖的N-酰基-2,3-苯并二氮杂平衍生物，其一般式为(I)，它们的立体异构体和酸盐，含有它们的药物组合物以及它们的制备方法。在一般式(I)中，R代表一个C.sub.1-6烷酰基，可选地被一个甲氧基，氰基，羧基，氨基，C.sub.1-4烷基氨基，二(C.sub.1-4烷基)氨基，吡咯烷基，邻苯二甲酰亚胺基或苯基取代，或者一个或多个卤素; 或者R是苯甲酰基，环丙烷羰基，C.sub.1-5烷基氨基甲酰基或苯基氨基甲酰基; 或者当N(3)和C(4)原子之间存在双键时，R不存在; R.sup.1代表氢; 或者当N(3)和C(4)原子之间存在双键时，R.sup.1不存在; R.sup.2代表一个C.sub.1-3烷基; 或者R.sup.1和R.sup.2一起代表一个亚甲基基团，N(3)和C(4)原子之间没有双键存在; R.sup.3代表氢或一个C.sub.1-4烷酰基; R.sup.4代表氢; 一个C.sub.1-6烷酰基，可选地被一个甲氧基，氰基，羧基，氨基，C.sub.1-4烷基氨基，二(C.sub.1-4烷基)氨基，吡咯烷基，邻苯二甲酰亚胺基或苯基或一个或多个卤素取代; 以及一个苯甲酰基，棕榈酰基，环丙烷羰基，C.sub.1-5烷基氨基甲酰基或苯基氨基甲酰基; 虚线代表可能存在的价键，但要注意的是，当R.sup.3和R.sup.4都代表氢时，N(3)和C(4)原子之间不存在双键。一般式(I)的化合物具有有价值的中枢神经系统效应，特别是肌肉松弛、抗惊厥和神经保护作用。因此，它们可能对治疗中枢神经系统起源的各种疾病有用。
• N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic
  申请人：Cyogyszerkutato Intezet KFT

  公开号：US05639751A1

  公开（公告）日：1997-06-17

  The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) R stands for a C.sub.1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C.sub.1-4 alkylamino, di(C.sub.1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C.sub.1-5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R.sup.1 means hydrogen; or R.sup.1 is absent when a double bond exists between the N(3) and C(4) atoms; R.sup.2 means a C.sub.1-3 alkyl group; or R.sup.1 and R.sup.2 together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R.sup.3 means hydrogen or a C.sub.1-4 alkanoyl group; R.sup.4 represents hydrogen; a C.sub.1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C.sub.1-4 alkylamino, di(C.sub.1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropanecarbonyl, C.sub.1-5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R.sup.3 and R.sup.4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

  该发明涉及一种新颖的N-酰基-2,3-苯并二氮杂平衍生物，其一般式为(I)，它们的立体异构体和酸盐，含有它们的药物组合物以及它们的制备方法。在一般式(I)中，R代表一个C.sub.1-6烷酰基，该基可选择性地被甲氧基，氰基，羧基，氨基，C.sub.1-4烷基氨基，二(C.sub.1-4烷基)氨基，吡咯烷基，邻苯二甲酰亚胺或苯基取代，或者被一个或多个卤素取代；或者R是苯甲酰基，环丙烷羰基，C.sub.1-5烷基氨基甲酰基或苯基氨基甲酰基；或者当N(3)和C(4)原子之间存在双键时，R不存在；R.sup.1代表氢；或者当N(3)和C(4)原子之间存在双键时，R.sup.1不存在；R.sup.2代表一个C.sub.1-3烷基基团；或者R.sup.1和R.sup.2一起代表一个亚甲基基团，并且N(3)和C(4)原子之间不存在双键；R.sup.3代表氢或一个C.sub.1-4烷酰基；R.sup.4代表氢；一个C.sub.1-6烷酰基，该基可选择性地被甲氧基，氰基，羧基，氨基，C.sub.1-4烷基氨基，二(C.sub.1-4烷基)氨基，吡咯烷基，邻苯二甲酰亚胺或苯基取代，或者被一个或多个卤素取代；以及一个苯甲酰基，棕榈酰基，环丙烷羰基，C.sub.1-5烷基氨基甲酰基或苯基氨基甲酰基；虚线代表可能存在的化合价键，但要注意的是，当R.sup.3和R.sup.4都代表氢时，N(3)和C(4)原子之间不存在双键。一般式(I)的化合物具有有价值的中枢神经系统效应，特别是肌肉松弛、抗惊厥和神经保护作用。因此，它们可能对治疗中枢神经系统起源的各种疾病有用。
• N acyl 2 3 benzodiazepine derivatives pharmaceutical compositions
  申请人：Gyogyszerkutato Intezet Kft.

  公开号：US05604223A1

  公开（公告）日：1997-02-18

  The invention relates to novel N-acyl-2,3-benzodiazepine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I), defined in this specification, a more complete description of the compounds may be found. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

  本发明涉及新型N-酰基-2,3-苯二氮平衍生物，其通式为(I)，其立体异构体和酸盐加合物，含有它们的制药组合物，以及它们的制备方法。在本说明书中定义的通式(I)中，可以找到化合物的更完整描述。通式(I)的化合物具有有价值的中枢神经系统效应，特别是肌肉松弛，抗惊厥和神经保护作用。因此，它们可能对治疗中枢神经系统起源的各种疾病有用。
• N-acyl-2,3-benzodiazepine derivatives pharmaceutical compositions
  申请人：Gyogyszerkutato Intezet KFT

  公开号：US05536832A1

  公开（公告）日：1996-07-16

  The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) R stands for a C.sub.1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C.sub.1-4 alkylamino, di(C.sub.1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C.sub.1-5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R.sup.1 means hydrogen; or R.sup.1 is absent when a double bond exists between the N(3) and C(4) atoms; R.sup.2 means a C.sub.1-3 alkyl group; or R.sup.1 and R.sup.2 together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R.sup.3 means hydrogen or a C.sub.1-4 alkanoyl group; R.sup.4 represents hydrogen; a C.sub.1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C.sub.1-4 alkylamino, di(C.sub.1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropane-carbonyl, C.sub.1-5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R.sup.3 and R.sup.4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

  本发明涉及一种新的N-酰基-2,3-苯并二氮平衍生物，其通式为（I），包括其立体异构体和酸盐加合物，其中R代表C.sub.1-6烷酰基，该基可以被一个或多个卤素取代，也可以被甲氧基、氰基、羧基、氨基、C.sub.1-4烷基氨基、二（C.sub.1-4烷基）氨基、吡咯烷基、邻苯二甲酰亚胺基或苯基取代；或者R是苯甲酰基、环丙烷羰基、C.sub.1-5烷基氨基酰基或苯基氨基酰基；或者当N（3）和C（4）原子之间存在双键时，R不存在；R.sup.1代表氢；或者当N（3）和C（4）原子之间存在双键时，R.sup.1不存在；R.sup.2代表C.sub.1-3烷基；或者R.sup.1和R.sup.2一起代表亚甲基基团，且N（3）和C（4）原子之间不存在双键；R.sup.3代表氢或C.sub.1-4烷酰基；R.sup.4代表氢；或者C.sub.1-6烷酰基，该基可以被一个或多个卤素取代，也可以被甲氧基、氰基、羧基、氨基、C.sub.1-4烷基氨基、二（C.sub.1-4烷基）氨基、吡咯烷基、邻苯二甲酰亚胺基或苯基取代；或者是苯甲酰基、棕榈酰基、环丙烷羰基、C.sub.1-5烷基氨基酰基或苯基氨基酰基；虚线代表可能存在的价键，但是当R.sup.3和R.sup.4都代表氢时，N（3）和C（4）原子之间不存在双键。通式（I）化合物具有有价值的中枢神经系统作用，特别是肌肉松弛、抗惊厥和神经保护作用。因此，它们可能对中枢神经系统疾病的治疗有用。